Previous 10 | Next 10 |
- Enrollment ongoing at multiple sites in the US and Europe; site initiation in Asia expected in November 2022 - - Enrollment on pace, with over 30% enrolled in the United States - - Topline data for RECOVER evaluating brilaroxazine for schizophrenia expected in mid-2023...
CUPERTINO, CA / ACCESSWIRE / October 13, 2022 / Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH), ("Reviva" or the "Company"), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory an...
CUPERTINO, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central n...
CUPERTINO, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central n...
Reviva Pharmaceuticals ( NASDAQ: RVPH ) entered agreement with a single healthcare-focused institutional investor , in an at-the-market priced direct offering for the purchase and sale of ~3.36M shares at $2.53. Gross proceeds total $8.5M. Warrants will have a...
CUPERTINO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central n...
Reviva Pharmaceuticals press release ( NASDAQ: RVPH ): Q2 GAAP EPS of -$0.29 (vs. -$0.12 Y/Y). As of Jun. 30, the company’s cash totaled approximately $19.4M. For further details see: Reviva Pharmaceuticals Q2 GAAP loss per share widens
- Enrollment on pace for ongoing pivotal Phase 3 RECOVER trial - - Topline data for RECOVER evaluating brilaroxazine for schizophrenia expected in mid-2023 – - $19.4 Million in Cash as of June 30, 2022 - CUPERTINO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- R...
Are you looking for penny stocks to add to your watch list? You’re not alone and there are plenty of cheap stocks to choose from. If you are looking at some of the most popular penny stocks today, you might’ve come across Graybug Vision, Inc (NASDAQ: GRAY ), Revelation Bio...
Enrollment remains on pace for Reviva’s Phase 3 clinical trial for the treatment of schizophrenia at 15 sites across the US with enrollment set to begin at sites in Europe and India in Q3 2022 More than 20% of the approximately 400 patients planned for Phase 3 trial...
News, Short Squeeze, Breakout and More Instantly...
Reviva Pharmaceuticals Holdings Inc. Company Name:
RVPH Stock Symbol:
NASDAQ Market:
Reviva Pharmaceuticals Holdings Inc. Website:
- Patent covers brilaroxazine use for treating pulmonary hypertension (PH), pulmonary arterial hypertension (PAH) in any patients including treating PH in patients with chronic obstructive pulmonary disease (COPD) or sickle cell disease (SCD) -Similar patents have also been granted in k...
2024-06-11 08:15:03 ET H.C. Wainwright analyst issues BUY recommendation for RVPH on June 11, 2024 06:40AM ET. The previous analyst recommendation was Buy. RVPH was trading at $1.45 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...
CUPERTINO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous ...